IN THE NEWS
Rare Disease Report: Spruce Launches CAH Natural History Study
Yesterday, in observance of Rare Disease Day, Spruce Biosciences announced the launch of the CAH Natural History Study, an initiative to advance knowledge and awareness of congenital adrenal hyperplasia (CAH).
Rare Daily by Global Genes: Spruce Begins Natural History Study of Rare Endocrine Disorder CAH
Spruce Biosciences said it has launched a natural history study of congenital adrenal hyperplasia, or CAH, a rare endocrine disorder caused by genetic mutations resulting in the inability to produce the critical stress hormone cortisol.
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company’s lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications
Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day
Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands